Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all- trans retinoic acid therapy

1997 ◽  
Vol 75 (5-6) ◽  
pp. 195-200 ◽  
Author(s):  
X. Thomas ◽  
B. Anglaret ◽  
A. Thiebaut ◽  
A. Belhabri ◽  
D. Treille-Ritouet ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Acid Therapy ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell’Adulto

2001 ◽  
Vol 19 (20) ◽  
pp. 4023-4028 ◽  
Author(s):  
Giorgina Specchia ◽  
Francesco Lo Coco ◽  
Marco Vignetti ◽  
Giuseppe Avvisati ◽  
Paola Fazi ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Retinoic Acid Receptor ◽  
Promyelocytic Leukemia ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Increased Risk ◽  
Junction Type ◽  
Wbc Count

PURPOSE: Recent reports of extramedullary disease (EMD) at recurrence in acute promyelocytic leukemia (APL) have raised increasing concern about a possible role of retinoic acid (RA) therapy. PATIENTS AND METHODS: We analyzed the risk of developing EMD localization at relapse in APL patients enrolled onto two consecutive studies of the Gruppo Italiano Malattie Ematologiche dell’Adulto. The studies investigated chemotherapy alone (LAP0389) versus RA plus chemotherapy (AIDA). RESULTS: When all relapse types were taken into account, 94 (51%) of 184 patients and 131 (18%) of 740 patients who attained hematologic remission underwent relapse in the LAP0389 and AIDA studies, respectively (P < .0001). EMD localization was documented in five (5%) of 94 and 16 (12%) of 131 patients (P = .08). Hematologic and/or molecular relapse was diagnosed concomitantly in all but two patients with EMD in the AIDA study. For patients in the LAP0389 and AIDA series, the probability of EMD localization of any type at relapse was 3% and 4.5%, respectively (P = .79), while the probability of CNS involvement was 0.6% and 2% (P = .28). No significant differences were found with regard to mean WBC count and promyelocytic leukemia/retinoic acid receptor-alpha junction type in comparisons of patients with EMD and hematologic relapse. CONCLUSION: APL patients receiving all-trans retinoic acid in addition to chemotherapy have no increased risk of developing EMD at relapse as compared with those treated with chemotherapy alone.

scholarly journals Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia

Blood ◽  
1991 ◽  
Vol 77 (8) ◽  
pp. 1657-1659 ◽  
Author(s):  
F Lo Coco ◽  
G Avvisati ◽  
D Diverio ◽  
MC Petti ◽  
M Alcalay ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
High Frequency ◽  
Southern Blot Analysis ◽  
Molecular Level ◽  
Promyelocytic Leukemia ◽  
Acid Therapy ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Leukemic Clone

Abstract The advent of retinoic acid (RA) in the treatment of acute promyelocytic leukemia (APL) has led to a high frequency of short- lasting complete remissions (CR). We studied the response to RA by molecularly analyzing the RA receptor alpha (RAR alpha) locus, which has recently been shown to be rearranged in all APLs. Southern blot analysis demonstrated that the RAR alpha rearrangements persisted in the APL samples containing maturing myeloid cells 2 to 3 weeks after the start of RA treatment, but disappeared after 5 to 8 weeks, when the patients achieved CR. Our investigations provide clear evidence that CR occurs at molecular level and that there is reconstitution of an apparently normal, nonclonal hematopoiesis. Further, it shows that RA acts by triggering differentiation rather than by exerting a cytotoxic effect on the leukemic clone.

Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia

2009 ◽  
Vol 91 (1) ◽  
pp. 132-135 ◽  
Author(s):  
Mariko Tanaka ◽  
Noriyasu Fukushima ◽  
Hidekazu Itamura ◽  
Chisako Urata ◽  
Masako Yokoo ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Acid Therapy ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

scholarly journals 4-Oxo Retinoic Acid for Refractory Acute Promyelocytic Leukemia in Children with All-Trans Retinoic Acid Therapy.

1995 ◽  
Vol 41 (4) ◽  
pp. 493-498 ◽  
Author(s):  
Kimitaka TAKITANI ◽  
Hiroshi TAMAI ◽  
Takao MORINOBU ◽  
Naohisa KAWAMURA ◽  
Munenori MIYAKE ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Acid Therapy ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Leukemia In Children

Ileal ulceration during all-trans-retinoic acid therapy for acute promyelocytic leukemia

2011 ◽  
Vol 35 (6) ◽  
pp. e89-e90
Author(s):  
Sanjeev K. Sharma ◽  
Pravas Mishra ◽  
Tulika Seth ◽  
Manoranjan Mahapatra
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Acid Therapy ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Acquired Resistance to All-Trans Retinoic Acid Therapy in Acute Promyelocytic Leukemia

1996 ◽  
Vol 19 (1) ◽  
pp. 10-13
Author(s):  
Monique Cornic ◽  
Laurent Delva ◽  
Sylvie Castaigné ◽  
Philippe Lefebvre ◽  
Nicole Balitrand ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Acquired Resistance ◽  
Promyelocytic Leukemia ◽  
Acid Therapy ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid
Sign in / Sign up

Export Citation Format

Share Document